The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2023 | MET-targeting therapies for NSCLC
Chul Kim, MD, MPH, Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC, discusses whether MET-targeting therapies might be an effective therapeutic option in the treatment of MET fusion-positive non-small cell lung cancer (NSCLC). Dr Kim also highlights the need for high-quality data from prospective studies in order to improve understanding of MET-targeting efficacy. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
